Learning Objectives:

1.  Measurable residual diseaase can be detected with multicolor cytometry or PCR-based methods.

2. Flow-MRD relies on the detection of leukemia-associated aberrant immunophenotype, while qPCR is a sensitive method for patients with specific gene mutations or translocations

3. Patients should get MRD assessment after 2 cycles of standard chemotherapy, (pre-transplant) and after the end of   treatment in PB and BM (post-transplant).

Session date: 
Monday, November 30, 2020 - 12:00pm to 1:00pm
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Caner Saygin, MD and Christopher Hourigan, MD, D.Phil